Jazz Pharmaceuticals/$JAZZ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
$JAZZ
Sector
Primary listing
Employees
2,800
Headquarters
Dublin, Ireland
Website
JAZZ Metrics
BasicAdvanced
$7.9B
-
-$6.63
0.24
-
Price and volume
Market cap
$7.9B
Beta
0.24
52-week high
$148.06
52-week low
$95.49
Average daily volume
816K
Financial strength
Current ratio
1.618
Quick ratio
1.151
Long term debt to equity
118.465
Total debt to equity
146.214
Interest coverage (TTM)
2.38%
Profitability
EBITDA (TTM)
1,419.54
Gross margin (TTM)
92.14%
Net profit margin (TTM)
-9.91%
Operating margin (TTM)
18.45%
Effective tax rate (TTM)
20.97%
Revenue per employee (TTM)
$1,460,000
Management effectiveness
Return on assets (TTM)
4.22%
Return on equity (TTM)
-10.84%
Valuation
Price to revenue (TTM)
1.934
Price to book
2.14
Price to tangible book (TTM)
-2.7
Price to free cash flow (TTM)
6.235
Free cash flow yield (TTM)
16.04%
Free cash flow per share (TTM)
20.776
Growth
Revenue change (TTM)
4.52%
Earnings per share change (TTM)
-211.89%
3-year revenue growth (CAGR)
5.49%
10-year revenue growth (CAGR)
12.33%
3-year earnings per share growth (CAGR)
99.18%
10-year earnings per share growth (CAGR)
4.89%
What the Analysts think about JAZZ
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
Bulls say / Bears say
The FDA approved Modeyso on August 6, 2025, as the first systemic therapy for H3 K27M-mutant diffuse midline glioma, expanding Jazz’s oncology portfolio into a high-unmet-need indication (Reuters)
Jazz settled with all 10 generic filers of Epidiolex, delaying the erosion of exclusivity until the very late 2030s and securing a prolonged revenue stream for its flagship epilepsy therapy (FiercePharma)
The $935 million acquisition of Chimerix adds the late-stage candidate dordaviprone, now under FDA review with an August 18, 2025 PDUFA date, diversifying and strengthening Jazz’s clinical pipeline (Reuters)
Jazz is paying a 72.4% premium to acquire Chimerix at $8.55 per share, raising concerns of potential overpayment and shareholder dilution (Reuters)
Oncology net product sales fell 11% year-over-year to $229.4 million in Q1 2025, driven by lower Zepzelca, Rylaze/Enrylaze and Defitelio sales amid competitive and protocol headwinds (Jazz Pharmaceuticals)
Jazz agreed to a $145 million settlement over antitrust claims tied to its key narcolepsy drug Xyrem, underlining ongoing legal risks and potential expense volatility (FiercePharma)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
JAZZ Financial Performance
Revenues and expenses
JAZZ Earnings Performance
Company profitability
JAZZ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jazz Pharmaceuticals stock?
Jazz Pharmaceuticals (JAZZ) has a market cap of $7.9B as of September 18, 2025.
What is the P/E ratio for Jazz Pharmaceuticals stock?
The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 0 as of September 18, 2025.
Does Jazz Pharmaceuticals stock pay dividends?
No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Jazz Pharmaceuticals dividend payment date?
Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.
What is the beta indicator for Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.